If You Have Hepatitis B, Should You Ask About HDV Testing Now?

If you know you have hepatitis B, the arrival of the first FDA-approved treatment for chronic hepatitis D (HDV) makes one question more practical than it was a few months ago: should you ask about hepatitis D testing?

The short answer is that it may be worth discussing with your clinician—especially if you’ve never been tested for HDV, have ongoing liver inflammation, or have other HDV risk factors. This doesn’t mean you should change your hepatitis B care on your own. It does mean that, once HDV is confirmed, there is now an FDA-approved option for some adults.

Why hepatitis D testing is tied to hepatitis B

Hepatitis D is unusual because it only occurs in people who also have hepatitis B. If a person does not have hepatitis B infection, they cannot get hepatitis D. The CDC also emphasizes that hepatitis B vaccination prevents hepatitis D by preventing hepatitis B in the first place.

When to suspect hepatitis D (and seek timely care)

The CDC notes that hepatitis D can cause illness that may be more severe than hepatitis B alone. Possible symptoms can include dark urine, fatigue, nausea, stomach pain, fever, joint pain, and yellowing of the skin or eyes (jaundice).

If you already have hepatitis B and you develop jaundice, dark urine, or rapidly worsening illness, seek prompt medical evaluation rather than waiting for a routine appointment.

CDC also describes two patterns: HDV can be acquired at the same time as hepatitis B, or it can happen later in someone who already has hepatitis B (sometimes called superinfection). The later pattern can be associated with more aggressive long-term liver disease.

So—who with hepatitis B should ask about HDV testing?

Many people with hepatitis B should consider asking. The goal is not broad population screening for everyone with HBV, but rather evaluation of people who may have HDV.

AASLD’s practical guidance describes a typical approach: HDV antibody testing first, followed by HDV RNA testing if the antibody test is positive. That confirmation step matters because antibodies can reflect exposure, while RNA testing helps determine whether infection is currently present.

It may be especially reasonable to bring up HDV testing if you have hepatitis B and:

Risk factors that increase HDV exposure (CDC lists examples such as injection drug use, sex exposure to an infected partner, HIV coinfection, hemodialysis, and occupational blood exposure)
Abnormal liver tests where the cause is not fully explained
Past time in places where hepatitis B and hepatitis D are more common

That said, “ask about testing” is not the same as “same-day emergency testing.” For most people, it’s a next-step conversation for primary care, infectious disease, or hepatology.

What the first FDA-approved HDV drug is (and who it’s for)

On May 22, 2026, the FDA announced approval of Hepcludex (bulevirtide-gmod) for chronic hepatitis D in adults who do not have cirrhosis or who have compensated cirrhosis.

Key practical details in the prescribing information include the approved dose and important safety monitoring recommendations. The label also notes this approval is based on accelerated approval—meaning the FDA relied on laboratory/virologic outcomes (for example, HDV RNA changes and ALT normalization), not on proven long-term outcomes such as preventing liver failure, liver cancer, transplant, or death.

Because of that, it’s reasonable for patients to ask clinicians what outcomes are expected in their individual situation and what follow-up schedule is recommended.

What the main phase 3 trial showed (and what it couldn’t yet prove)

The FDA approval was supported by a phase 3 randomized, open-label trial comparing immediate vs delayed treatment. In the trial, a combined response endpoint was achieved by a substantially higher portion of people given immediate treatment than those given delayed treatment at week 48.

The FDA label and a concise JAMA summary also describe HDV RNA reduction over time, with virologic response increasing among those who received ongoing treatment.

These results are encouraging, but the study design and endpoints mean it does not yet settle long-term “hard outcome” questions. That uncertainty is exactly why ongoing evidence matters after accelerated approvals.

Important safety point: don’t stop without a plan

The prescribing information includes a boxed warning: stopping Hepcludex can lead to severe acute flare-ups of both hepatitis D and hepatitis B, particularly in people with cirrhosis. The label recommends close clinical and laboratory follow-up after discontinuation (for at least six months).

Common side effects listed in the label include injection-site reactions and other effects such as headache, abdominal pain, fatigue, and itching. Hypersensitivity reactions—including anaphylaxis—are also described.

Because HDV occurs only with HBV, the label also emphasizes managing underlying hepatitis B as clinically appropriate.

How many people might be affected?

CDC notes that the exact number of U.S. HDV cases is uncertain because hepatitis D is not nationally notifiable. That means clinicians and public-health systems rely on a mix of testing, specialty reporting, and clinical detection—not a single complete national count.

What reasonable next steps look like

If you have hepatitis B and have never been tested for HDV, ask your clinician whether HDV testing is appropriate for you.
If you get an HDV antibody positive result, ask whether HDV RNA confirmation has been done or is planned.
If you’re having symptoms such as jaundice or dark urine (or you feel you’re worsening quickly), seek timely medical evaluation.
If you are eligible for it, ask about hepatitis B vaccination—preventing hepatitis B is also preventing hepatitis D.
Do not start, stop, or change hepatitis B or HDV-related medications without clinician guidance. The new HDV drug has a boxed warning and decisions depend on liver status and your broader HBV management.

The bottom line

The first FDA-approved HDV treatment is a meaningful milestone for a rare, serious infection that occurs only in people with hepatitis B. But it does not mean everyone with hepatitis B needs HDV treatment, and it does not yet prove long-term clinical benefit. What it does change is the testing conversation: asking about HDV evaluation may now be more actionable than it was before.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.